• Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group 

      Gregersen, Henrik; Peceliunas, Valdas; Remes, Kari; Schjesvold, Fredrik Hellem; Abildgaard, Niels; Nahi, Hareth; Andersen, Niels Frost; Vangsted, Annette Juul; Klausen, Tobias Wirenfeldt; Helleberg, Carsten; Carlson, Kristina; Frølund, Ulf Christian; Axelsson, Per; Stromberg, Olga; Blimark, Cecilie Hveding; Crafoord, Jacob; Tsykunova, Galina; Eshoj, Henrik Rode; Waage, Anders; Hansson, Markus; Gulbrandsen, Nina (Peer reviewed; Journal article, 2021)
      Objective We investigated the efficacy and safety of carfilzomib-containing induction before salvage high-dose melphalan with autologous stem-cell transplantation (salvage ASCT) and maintenance with carfilzomib and ...
    • Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial 

      Schmitz, Alexander; Brøndum, Rasmus Froberg; Johnsen, Hans Erik; Mellqvist, Ulf-Henrik; Waage, Anders; Gimsing, Peter; Op Bruinink, Davine Hofste; van der Velden, Vincent; van der Holt, Bronno; Hansson, Markus; Andersen, Niels Frost; Frølund, Ulf Christian; Helleberg, Carsten; Schjesvold, Fredrik Hellem; Ahlberg, Lucia; Gulbrandsen, Nina; Andreasson, Bjorn; Lauri, Birgitta; Haukås, Einar; Bødker, Julie Støve; Roug, Anne Stidsholt; Bøgsted, Martin; Severinsen, Marianne T.; Gregersen, Henrik; Abildgaard, Niels; Sonneveld, Pieter; Dybkær, Karen (Peer reviewed; Journal article, 2022)
      Background Multiple myeloma remains an incurable disease with multiple relapses due to residual myeloma cells in the bone marrow of patients after therapy. Presence of small number of cancer cells in the body after cancer ...